Men and women have different genetic risk factors for developing brain cancer

June 28, 2018, Case Western Reserve University
Credit: CC0 Public Domain

Glioma is the most common type of primary malignant brain tumor in the United States; glioblastoma being the most common type of glioma in adults. While sex differences in the incidence and survival rates of glioma were known, researchers had not investigated whether genetic differences based on sex could cast light on potential differences in the risk profile of glioma between men and women.

Now, a team from Case Western Reserve University School of Medicine, together with an international consortium of researchers, have discovered that men and women have different genetic risk factors for developing glioma.

The research was recently published in Scientific Reports. The study involved the work of more than 35 investigators representing more than 30 universities, institutes and government agencies worldwide.

"Sex-stratified analyses in studies such as this can reveal novel insights into the known in glioma and provide previously unknown genetic risk associations," said Jill Barnholtz-Sloan, Sally S. Morley Designated Professor in Brain Tumor Research at Case Western Reserve University School of Medicine, Associate Director for Bioinformatics at Case Comprehensive Cancer Center, and Associate Director for Translational Informatics at the Institute for Computational Biology. "This finding could provide an avenue to gaining a better understanding of sex differences in brain tumor incidence, and may also suggest varying mechanisms and pathways of the disease."

The consortium looked at the among all glioma, glioblastoma only and non-glioblastoma patients based on their sex. Quinn Ostrom, Ph.D., came up with the idea for the study while she was a graduate assistant for Barnholtz-Sloan. Ostrom now is doing post-doctoral work in cancer epidemiology at Baylor College of Medicine in Houston, Texas.

The researchers found three regions in the genome where significant genetic differences between men and women existed, and these differences also varied by sex and type of tumor (glioblastoma vs. non-glioblastoma). "There's one where it's clearly associated with an increased risk in males, one where it's clearly associated with an increased risk in females, and one where it's showing in both males and females, but it seems to have a stronger association in females," Barnholtz-Sloan said.

Though early in the process of understanding the genetic sources of sex based differences in malignant , the recent analysis could help define a path to a genetic test that helps doctors assess patient risk for brain cancer.

"We were surprised to find a large region in the genome associated with glioma and specifically glioblastoma in females only," Barnholtz-Sloan said. "This region had not previously been associated with gliomas, although other similar genome-wide associated studies have identified associations at this region for a variety of traits, including several autoimmune diseases, as well as increased age at menarche." As the study discussion notes, if increased lifetime estrogen exposure decreases glioma risk, as some have hypothesized, it is possible that variants which increase age at menarche (potentially decreasing total estrogen exposure) may increase risk in females.

Explore further: New genetic risk factors identify two distinct glioma subtypes

More information: Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21, Scientific Reports (2018). DOI: 10.1038/s41598-018-24580-z

Related Stories

New genetic risk factors identify two distinct glioma subtypes

March 27, 2017
An international consortium of researchers led by Dr. Melissa Bondy, professor of medicine, associate director for population sciences at the Dan L Duncan Comprehensive Cancer Center and McNair Scholar at Baylor College of ...

International 'A' team debuts brain cancer atlas

June 6, 2018
It takes an "A" team to make headway against glioblastoma, a highly aggressive type of brain cancer. Glioblastoma is the most common type of malignant brain tumor in adults. In addition to the caliber of the researchers involved, ...

Researchers find leukemia and lymphoma drug may benefit glioblastoma patients

May 30, 2018
New Cleveland Clinic research shows for the first time that ibrutinib, an FDA-approved drug for lymphoma and leukemia, may also help treat the most common—and deadliest—type of brain tumor. The findings, published in ...

Areas of glioblastoma tumors correlate with separate subtypes of glioma stem cells

October 10, 2017
A new study published in the Oct. 9 issue of the journal Nature Medicine demonstrates, for the first time, that glioblastoma (GBM), the most common and most lethal brain tumor, is driven by two distinct subsets of cancer ...

Major study finds five new genetic variants linked to brain cancer

October 1, 2015
The biggest ever study of DNA from people with glioma - the most common form of brain cancer - has discovered five new genetic variants associated with the disease.

Scientists target glioma cancer stem cells, which could improve patient survival

February 5, 2018
Glioblastoma multiforme is the most common and aggressive primary brain tumor and has one of the worst survival rates of all cancers. Despite surgery, radiation and chemotherapy, these tumors virtually always become resistant ...

Recommended for you

From the ashes of a failed pain drug, a new therapeutic path emerges

November 16, 2018
In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, Ph.D., and chemist Kai Johnsson, Ph.D., his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. ...

Repurposing FDA-approved drugs can help fight back breast cancer

November 16, 2018
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...

Traditional chemotherapy superior to new alternative for oropharyngeal cancers

November 16, 2018
A drug increasingly used in combination with radiotherapy to treat a type of cancer that forms in the tonsils or the base of the tongue is inferior to a previously favored option, according to a large, clinical trial led ...

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.